Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rhinovirus Infection - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Rhinovirus Infection - Pipeline Review, H1 2016', provides an overview of the Rhinovirus Infection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhinovirus Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infection and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infection - The report reviews pipeline therapeutics for Rhinovirus Infection by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Rhinovirus Infection therapeutics and enlists all their major and minor projects - The report assesses Rhinovirus Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Rhinovirus Infection Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rhinovirus Infection Overview 7 Therapeutics Development 8 Pipeline Products for Rhinovirus Infection - Overview 8 Pipeline Products for Rhinovirus Infection - Comparative Analysis 9 Rhinovirus Infection - Therapeutics under Development by Companies 10 Rhinovirus Infection - Therapeutics under Investigation by Universities/Institutes 11 Rhinovirus Infection - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Rhinovirus Infection - Products under Development by Companies 14 Rhinovirus Infection - Products under Investigation by Universities/Institutes 15 Rhinovirus Infection - Companies Involved in Therapeutics Development 16 AIMM Therapeutics B.V. 16 Biological Mimetics, Inc. 17 Biota Pharmaceuticals, Inc. 18 Boehringer Ingelheim GmbH 19 Johnson & Johnson 20 Novartis AG 21 Theraclone Sciences, Inc. 22 Rhinovirus Infection - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 BNT-014 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 KR-22809 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibodies for Human Rhinovirus Infections - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 OBR-5340 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 PL-402 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Recombinant Peptide for Rhinovirus Infection - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules for Rhinovirus Infections - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit RNA Polymerase for Rhinovirus and Picornaviridae Infections - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 vapendavir - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Rhinovirus Infection - Recent Pipeline Updates 46 Rhinovirus Infection - Dormant Projects 48 Rhinovirus Infection - Product Development Milestones 49 Featured News & Press Releases 49 Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial 49 Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 49 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for Rhinovirus Infection, H1 2016 8 Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Rhinovirus Infection - Pipeline by AIMM Therapeutics B.V., H1 2016 16 Rhinovirus Infection - Pipeline by Biological Mimetics, Inc., H1 2016 17 Rhinovirus Infection - Pipeline by Biota Pharmaceuticals, Inc., H1 2016 18 Rhinovirus Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2016 19 Rhinovirus Infection - Pipeline by Johnson & Johnson, H1 2016 20 Rhinovirus Infection - Pipeline by Novartis AG, H1 2016 21 Rhinovirus Infection - Pipeline by Theraclone Sciences, Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Rhinovirus Infection Therapeutics - Recent Pipeline Updates, H1 2016 46 Rhinovirus Infection - Dormant Projects, H1 2016 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
